Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deal With Arcellx Gives Gilead New Beachhead In Multiple Myeloma

Executive Summary

Deal Snapshot: Months after terminating its Phase I BCMA-targeting CAR-T program and on the eve of ASH, Gilead’s Kite announced a deal with Arcellx for a CAR-T that has already shown promising data.

You may also be interested in...



A Neato Cell: Data Show Favorable Efficacy, Toxicity For Arcellx/Gilead Myeloma CAR-T

Anito-cel showed strong efficacy in heavily pretreated patients despite characteristics predicting poorer performance, but none of the atypical neurotoxicities that have appeared with other BCMA CAR-Ts.

Gilead’s Kite, Arcellx Expand BCMA CAR-T Partnership Into Lymphomas

The amendment to a December 2022 deal expands their myeloma CAR-T partnership and will see development of CART-ddBCMA in lymphomas, where research indicates anti-BCMA therapy has activity.

Gilead’s TIGIT Program Perks Up After Lung Cancer Letdown

The drug maker announced early data for zimberelimab/domvanalimab in gastrointestinal cancers that it called encouraging, though an analyst was more skeptical due to limited interpretability.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC147509

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel